Marinus Pharmaceuticals Inc
(NASDAQ : MRNS)

( )
MRNS After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Binary Options?
We'll teach you the best ways to trade binaries.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Other
symbolcompany%chnglast%shortavg$volume
AMRNAmarin Corporation Plc Sponsored ADR
1.68%17.522.0%$170.25m
SAGESAGE Therapeutics, Inc.
-1.79%137.299.5%$121.17m
PRGOPerrigo Co. Plc
-2.26%44.936.8%$100.11m
JAZZJazz Pharmaceuticals Plc
-0.32%128.662.2%$87.44m
GWPHGW Pharmaceuticals PLC Sponsored ADR
1.44%139.266.3%$78.73m
PTLAPortola Pharmaceuticals, Inc.
-3.77%25.537.7%$54.93m
ICPTIntercept Pharmaceuticals, Inc.
-2.22%110.9318.6%$52.57m
AXSMAxsome Therapeutics, Inc.
4.41%8.522.7%$46.12m
MNKMallinckrodt Plc
-3.15%19.9821.1%$40.05m
CTLTCatalent Inc
-0.62%35.392.4%$39.43m
ICLRICON Plc
-0.68%132.284.1%$38.89m
UTHRUnited Therapeutics Corporation
-1.60%113.9014.4%$34.98m
ENDPEndo International Plc
-4.23%9.298.9%$32.66m
HZNPHorizon Pharma plc
0.37%21.927.4%$26.48m
PCRXPacira Pharmaceuticals, Inc.
1.05%40.4610.6%$25.36m

Company Profile

Marinus Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the identification and development of neuropsychiatric therapeutics. Its clinical stage drug product candidate, ganaxolone, is a positive allosteric modulator being developed in three different dose forms: intravenous, capsule, and liquid. The company was founded by Geoffrey E. Chaiken, Harry H. Penner Jr., Vincent A. Pieribone and Kenneth R. Shaw on August 14, 2003 and is headquartered in Radnor, PA.